Amgen Inc. (AMGN): Price and Financial Metrics
Amgen Inc. (AMGN)
Today's Latest Price: $246.33 USD
Updated Sep 28 1:26pm
Add AMGN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
AMGN Stock Summary
- AMGN has a higher market value than 98.83% of US stocks; more precisely, its current market capitalization is $142,803,856,220.
- Amgen Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.87% of US equities in our set.
- In terms of volatility of its share price, AMGN is more volatile than only 2.23% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Amgen Inc, a group of peers worth examining would be AZN, LLY, TXN, BMY, and SNY.
- AMGN's SEC filings can be seen here. And to visit Amgen Inc's official web site, go to www.amgen.com.
AMGN Stock Price Chart Technical Analysis Charts
AMGN Price/Volume Stats
| Current price | $246.33 | 52-week high | $264.97 |
| Prev. close | $243.82 | 52-week low | $177.05 |
| Day low | $244.77 | Volume | 683,118 |
| Day high | $249.04 | Avg. volume | 2,881,532 |
| 50-day MA | $246.12 | Dividend yield | 2.62% |
| 200-day MA | $232.02 | Market Cap | 144.27B |
Amgen Inc. (AMGN) Company Bio
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company was founded in 1980 and is based in Thousand Oaks, California.
AMGN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $246.33 | $215.09 | -12% |
We started the process of determining a valid price forecast for Amgen Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amgen Inc ranked in the 41th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Amgen Inc ended up being:
- The company has produced more trailing twelve month cash flow than 95% of its sector Healthcare.
- Amgen Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 21.38% of tickers in our DCF set.
- AMGN's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than just 21.38% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -14% |
| 1% | -13% |
| 2% | -12% |
| 3% | -11% |
| 4% | -10% |
| 5% | -9% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMGN, try DGX, STE, FONR, PRGO, and PAHC.
Loading social stream, please wait...